- Email: [email protected]
5422274 Internal deletion mutants of soluble T4(CD4)
304
PATENT ABSTRACTS
88% yield of plutonium from soils. Further, pertinent gene(s) encoding enzymes obtainable from iron-reducing microbes can be used by placing such gene(s) on a suitable vector and transforming a competent host. The transformed host then can be used in the same manner as the native bacterium.
5422274 INTERNAL DELETION MUTANTS OF SOLUBLE T4(CD4) Maddon Paul J; Axel Richar; Sweet Raymond; A_rthos Jame New York, NY, UNITED STATES Assigned to The Trustees of Columbia University in the City of New York; SmithKline Beckman Corporati This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method treats the subject with an effective amount of a pharmaceutical composition having an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.
5422275 PROTEIN PRODUCTION AT SYNTHETIC START SITE Nunherg Jack; Chang Annie C; Cohen Stanley; Schimke Robert Oakland, CA, UNITED STATES Assigned to The Board of Trustees of the Leland Stanford Jr University
Methods and compositions are provided for producing heterologous proteins in a micrcorganism host, particularly bacterium, without fusion to an endogenous protein. Particularly, the heterologous gene may be inserted into a vector comprising an endogenous gene, where the heterologous gene is preceded by a ribosomal binding site. A heterologous enzyme functional in a bacterial host is demonstrated.
5422427 PNEUMOCOCCAL FIMBRIAL PROTEIN A Russell Harol; Sampson Jacquely; O'Connor Steven P Atlanta, GA, UNITED STATES Assigned to The United States of America as represented by the United States Department of Health and Human Services The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.
5422428 IMMUNIZATION AGAINST BABESIOSIS USING PURIFIED SURFACE ANTIGENS OF BABESIA BIGEMINA AND SIMILAR IMMUNOGENS McGuire Travis C; McElwain Terry F; Perryman Lance E; Davis William C Pullman, WA, UNITED STATES Assigned to Washington State University Antigenic surface proteins from the intraerythrocytic merozoite stage of Babesia bigemina have been isolated using cell fusions and monoclonal antibodies produced thereby. The gene encoding a 58 kD surface protein has been identified and the DNA sequence determined and compared with sequences of other known
PATENT ABSTRACTS
88% yield of plutonium from soils. Further, pertinent gene(s) encoding enzymes obtainable from iron-reducing microbes can be used by placing such gene(s) on a suitable vector and transforming a competent host. The transformed host then can be used in the same manner as the native bacterium.
5422274 INTERNAL DELETION MUTANTS OF SOLUBLE T4(CD4) Maddon Paul J; Axel Richar; Sweet Raymond; A_rthos Jame New York, NY, UNITED STATES Assigned to The Trustees of Columbia University in the City of New York; SmithKline Beckman Corporati This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method treats the subject with an effective amount of a pharmaceutical composition having an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.
5422275 PROTEIN PRODUCTION AT SYNTHETIC START SITE Nunherg Jack; Chang Annie C; Cohen Stanley; Schimke Robert Oakland, CA, UNITED STATES Assigned to The Board of Trustees of the Leland Stanford Jr University
Methods and compositions are provided for producing heterologous proteins in a micrcorganism host, particularly bacterium, without fusion to an endogenous protein. Particularly, the heterologous gene may be inserted into a vector comprising an endogenous gene, where the heterologous gene is preceded by a ribosomal binding site. A heterologous enzyme functional in a bacterial host is demonstrated.
5422427 PNEUMOCOCCAL FIMBRIAL PROTEIN A Russell Harol; Sampson Jacquely; O'Connor Steven P Atlanta, GA, UNITED STATES Assigned to The United States of America as represented by the United States Department of Health and Human Services The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.
5422428 IMMUNIZATION AGAINST BABESIOSIS USING PURIFIED SURFACE ANTIGENS OF BABESIA BIGEMINA AND SIMILAR IMMUNOGENS McGuire Travis C; McElwain Terry F; Perryman Lance E; Davis William C Pullman, WA, UNITED STATES Assigned to Washington State University Antigenic surface proteins from the intraerythrocytic merozoite stage of Babesia bigemina have been isolated using cell fusions and monoclonal antibodies produced thereby. The gene encoding a 58 kD surface protein has been identified and the DNA sequence determined and compared with sequences of other known